Padrão E, Araújo D, Todo Bom A, Robalo Cordeiro C, Correia de Sousa J, Cardoso J, Morais-Almeida M, Costa R, Pavão F, Leite R B, Marques A
Institute of Health Sciences, Universidade Católica Portuguesa, Portugal; Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal.
Institute of Health Sciences, Universidade Católica Portuguesa, Portugal; Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal.
Pulmonology. 2018 May/June;24(3):174-181. doi: 10.1016/j.rppnen.2017.11.009. Epub 2018 Jan 12.
The overlap between asthma and chronic obstructive pulmonary disease (COPD) (ACO) has been discussed for many years but clinical recommendations for this entity have been diverse. This study is intended to reach a consensus on diagnosis, treatment and patient orientation for ACO, within the Portuguese medical community.
This study was conducted by a multidisciplinary panel of experts from three distinct medical specialties (Pulmonology, Family Medicine and Immunoallergology). This panel selected a total of 190 clinicians, based on their expertise in obstructive airway diseases, to participate in a Delphi structured survey with three rounds of questionnaires. These results were ultimately discussed, in a meeting with the panel of experts and some of the study participants, and consensus was reached in terms of classification criteria, treatment and orientation of ACO patients.
The majority of clinicians (87.2%) considered relevant the definition of an overlap entity between asthma and COPD. A consensus was achieved on the diagnosis of ACO - presence of simultaneous clinical characteristics of asthma and COPD together with a fixed airflow obstruction (FEV1/FVC<0.7) associated with 2 major criteria (previous history of asthma; presence of a previous history of smoking exposure and/or exposure to biomass combustion; positive bronchodilation test (increase in FEV of at least 200mL and 12%) on more than 1 occasion) plus 1 minor criteria (history of atopy; age ≥40 years; peripheral eosinophilia (>300eosinophils/μL or >5% of leukocytes); elevation of specific IgEs or positive skin tests for common allergens). A combination of inhaled corticosteroid (ICS) with long-acting beta2-agonist (LABA) or long-acting muscarinic antagonist (LAMA) was considered as first line pharmacological treatment. Triple therapy with ICS plus LABA and LAMA should be used in more severe or symptomatic cases. Non-pharmacological treatment, similar to what is recommended for asthma and COPD, was also considered highly important. A hospital referral of ACO patients should be made in symptomatic or severe cases or when there is a lack of diagnostic resources.
This study highlights the relevance of defining ACO, within the Portuguese medical community, and establishes diagnostic criteria that are important for future interventional studies. Recommendations on treatment and patient's orientation were also achieved.
哮喘与慢性阻塞性肺疾病(COPD)重叠综合征(ACO)已被讨论多年,但针对该病症的临床建议却各不相同。本研究旨在就ACO在葡萄牙医学界的诊断、治疗及患者指导方面达成共识。
本研究由来自三个不同医学专业(肺病学、家庭医学和免疫过敏学)的多学科专家小组开展。该小组基于其在阻塞性气道疾病方面的专业知识,共挑选了190名临床医生参与一项三轮问卷的德尔菲结构化调查。这些结果最终在与专家小组及部分研究参与者的会议上进行了讨论,并在ACO患者的分类标准、治疗及指导方面达成了共识。
大多数临床医生(87.2%)认为哮喘与COPD重叠实体的定义具有相关性。就ACO的诊断达成了共识——同时具备哮喘和COPD的临床特征,以及与2项主要标准(既往哮喘病史;既往有吸烟暴露史和/或生物质燃烧暴露史;多次支气管舒张试验阳性(FEV增加至少200mL且12%))加1项次要标准(特应性病史;年龄≥40岁;外周血嗜酸性粒细胞增多(>300嗜酸性粒细胞/μL或>白细胞的5%);特异性IgE升高或常见变应原皮肤试验阳性)相关的固定气流受限(FEV1/FVC<0.7)。吸入性糖皮质激素(ICS)与长效β2受体激动剂(LABA)或长效毒蕈碱拮抗剂(LAMA)联合使用被视为一线药物治疗。对于病情更严重或有症状的病例,应使用ICS加LABA和LAMA的三联疗法。非药物治疗,与哮喘和COPD的推荐治疗类似,也被认为非常重要。有症状或病情严重的ACO患者,或在缺乏诊断资源时,应转诊至医院。
本研究凸显了在葡萄牙医学界定义ACO的相关性,并确立了对未来干预性研究很重要的诊断标准。同时也达成了关于治疗和患者指导的建议。